君实生物(01877.HK) 公布,收到国家药品监督管理局通知书,注射用JS212的临床试验申请获得批准,同意本品单药在晚期实体瘤患者中开展临床试验。JS212是重组人源化抗表皮生长因子受体和人表皮生长因子受体3双特异性抗体偶联药物,主要用于晚期恶性实体瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-20 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.